



Therapeutics Advisory Council
Inaugural Meeting
New York, September 9, 2025

Participants (in person):

- Bruce Bebo, Executive VP Research – National Multiple Sclerosis Society
- Stacie Bell, Chief Clinical Research Officer – Lupus Therapeutics
- Guy Eakin, Chief Scientific & Medical Officer – National Psoriasis Foundation
- Ilana Golant, CEO – Food Allergy Fund
- Greg Gordon, Chief Medical Officer – Scleroderma Research Foundation
- Andres Hurtado-Lorenzo, Senior VP Translational Research – IBD Ventures/CCF
- Schalon Newton, Principal – Immune Boost Capital
- Teo Staeva, CSO – Lupus Research Alliance
- Susan Weissman, Board Chair – Food Allergy Fund
- Deann Wright, Board Member – Scleroderma Research Foundation
- Franck Barrat, Director of the Inflammation and Autoimmunity Program – HSS
- Daina Graybosch, Senior Managing Director – Leerink Partners
- Mark Lehmann, CEO – Citizens JMP, LLC
- Lou DeGennaro – Vie Ventures (Senior Advisor)
- Luke Evnin – Vie Ventures (Co-Founder & Senior Advisor)
- Jolyon Martin – Vie Ventures (Investment Team/Strategic Collaborations)
- Steven St. Peter – Vie Ventures (Co-Founder & Managing Director)
- Tiberend Associates (Casey McDonald, Jason Rando, Eric Reiss, Greg Tiberend)

Participants (virtual):

- Tim Coetzee (CEO, National MS Society)
- Michael Osso (CEO, Crohn's & Colitis Foundation)
- Janet Church (CEO, Sjogren's Foundation)
- Alice Bast (CEO, Beyond Celiac)
- Emile Stormoen (CEO, Arthritis National Research Foundation)
- Joanne Gold (Executive Director of Scleroderma Research Foundation)
- Sean Doherty (Founder and former Chair of T1D Fund; President, T1D Action)
- Steven Neier (Dana Farber Binney Street Capital, Vie Ventures)

AGENDA

Framing Session: 9:00 - 9:30am

- **Purpose:** Establish a shared context for the day's discussions and reinforce the unique purpose of the TAC
- **Facilitator:** Jolyon Martin
- **Content:**
 - Welcome from Luke Evnin and Steven St. Peter
 - Introduction to and context setting for the day

Scientific Deep Dive "Fibrosis Across Autoimmune Diseases": 9:30 – 11:00am

- **Facilitator:** Lou DeGennaro
- **Session Format:** Short presentations by participating collaborators
- **Goal:** Highlight how fibrosis presents, progresses, and is therapeutically targeted across diseases
- **Intended Outcomes:**
 - Knowledge-sharing between foundations
 - Identify shared biological mechanisms and translational hurdles
 - Discuss where cross-indication investment opportunities may exist

BREAK: 11:00-11:15 am

Organizational Practice-Sharing Panel: 11:15 am – 12:30 pm

- **Purpose:** A structured peer discussion to compare how each foundation engages with industry and supports therapeutic development
- **Format:** Individual presentations followed by group discussion
- **Key Questions to Explore:**
 - How does your organization engage with biotech companies?
 - How does your organization engage with pharma/industry?
 - Are there areas or projects where you wish to collaborate with other SCs or best practices that you wish to share?

- **Objective:** Highlight replicable tools and surface best practices

LUNCH: 12:30pm – 1:30pm

Brainstorming: Future TAC Themes and Collaborative Areas: 1:30 – 2:00 pm

- **Format:** Open discussion
- **Prompts:**
 - What are the shared scientific and operational questions we should tackle in future TACs?
 - Potential areas include patient stratification, early-stage screening, clinical trial networks, or shared biomarker validation
- **Objective:** Ensure future meetings have high-value content

Panel Discussion: 2:00 – 3:00 pm

- **Participants:**
 - Franck Barrat, Director of the Inflammation and Autoimmunity Program – HSS
 - Luke Evnin, Co-Founder Vie Ventures, Co-Founder MPM, Chair SRF
 - Daina Graybosch, Senior Managing Director – Leerink Partners
 - Mark Lehmann, CEO – Citizens JMP, LLC
- **Moderator:** Steven St. Peter
- **Discussion Topic:** "The Funding Environment: Discovery Research, Venture Capital, Public Markets and Partnering with Big Pharma"

Wrap up session: 3:00 – 4:00 pm

- **Participants:** In-person attended + virtual attendance
- **Purpose:** Summarise the discussions of the day and any key next steps
- **Facilitators:** Steven St. Peter + Lou DeGennaro
- **Format:** Facilitators summary; participants share one thing they took from the day

Happy Hour: 4:00 – 5:00 pm

END OF TAC MEETING